Concepts in radioimmunotherapy and immunotherapy

Radioimmunotherapy from a Lym-1 perspective

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Conventional chemotherapy regimens cure fewer than 50% of patients with aggressive non-Hodgkin's lymphoma, and fewer than 5% of patients with indolent lymphomas. However, the majority of patients remain responsive to remarkably low doses of external beam radiotherapy. A logical strategy for the treatment of non-Hodgkin's lymphoma is radioimmunotherapy (RIT); systemic radiation targeted to tumor cells using monoclonal antibodies. RIT involves continuous exposure to low-dose-rate radiation, with the intensity of the dose decreasing over time, and as such is distinct from conventional radiotherapy and chemotherapy. RIT has several advantages over monoclonal antibody therapy. For example, a functional immune system is not an absolute requirement to kill tumor cells, and, depending on the radiolabel used, β-emissions are effective over 100 to 500 cell diameters, resulting in a crossfire effect on nearby tumor cells. The crossfire effect enables the eradication of cells that are not necessarily targeted by the antibody, but are affected by the radiation. The success of RIT depends on which antibody and radioisotope is used. This article examines how the antibody, radioisotope, chelator, and linker affect the safety and efficacy of RIT. The different approaches to dosing are also considered.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume32
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 2005

Fingerprint

Radioimmunotherapy
Immunotherapy
Radiation
Radioisotopes
Non-Hodgkin's Lymphoma
Antibodies
Radiotherapy
Monoclonal Antibodies
Drug Therapy
Neoplasms
Chelating Agents
Immune System
Lymphoma
Safety
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Concepts in radioimmunotherapy and immunotherapy : Radioimmunotherapy from a Lym-1 perspective. / Denardo, Gerald L.

In: Seminars in Oncology, Vol. 32, No. SUPPL. 1, 02.2005.

Research output: Contribution to journalArticle

@article{2c0d50a1ec26449fa365ef3ad7934cb7,
title = "Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective",
abstract = "Conventional chemotherapy regimens cure fewer than 50{\%} of patients with aggressive non-Hodgkin's lymphoma, and fewer than 5{\%} of patients with indolent lymphomas. However, the majority of patients remain responsive to remarkably low doses of external beam radiotherapy. A logical strategy for the treatment of non-Hodgkin's lymphoma is radioimmunotherapy (RIT); systemic radiation targeted to tumor cells using monoclonal antibodies. RIT involves continuous exposure to low-dose-rate radiation, with the intensity of the dose decreasing over time, and as such is distinct from conventional radiotherapy and chemotherapy. RIT has several advantages over monoclonal antibody therapy. For example, a functional immune system is not an absolute requirement to kill tumor cells, and, depending on the radiolabel used, β-emissions are effective over 100 to 500 cell diameters, resulting in a crossfire effect on nearby tumor cells. The crossfire effect enables the eradication of cells that are not necessarily targeted by the antibody, but are affected by the radiation. The success of RIT depends on which antibody and radioisotope is used. This article examines how the antibody, radioisotope, chelator, and linker affect the safety and efficacy of RIT. The different approaches to dosing are also considered.",
author = "Denardo, {Gerald L}",
year = "2005",
month = "2",
doi = "10.1053/j.seminoncol.2005.01.011",
language = "English (US)",
volume = "32",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Concepts in radioimmunotherapy and immunotherapy

T2 - Radioimmunotherapy from a Lym-1 perspective

AU - Denardo, Gerald L

PY - 2005/2

Y1 - 2005/2

N2 - Conventional chemotherapy regimens cure fewer than 50% of patients with aggressive non-Hodgkin's lymphoma, and fewer than 5% of patients with indolent lymphomas. However, the majority of patients remain responsive to remarkably low doses of external beam radiotherapy. A logical strategy for the treatment of non-Hodgkin's lymphoma is radioimmunotherapy (RIT); systemic radiation targeted to tumor cells using monoclonal antibodies. RIT involves continuous exposure to low-dose-rate radiation, with the intensity of the dose decreasing over time, and as such is distinct from conventional radiotherapy and chemotherapy. RIT has several advantages over monoclonal antibody therapy. For example, a functional immune system is not an absolute requirement to kill tumor cells, and, depending on the radiolabel used, β-emissions are effective over 100 to 500 cell diameters, resulting in a crossfire effect on nearby tumor cells. The crossfire effect enables the eradication of cells that are not necessarily targeted by the antibody, but are affected by the radiation. The success of RIT depends on which antibody and radioisotope is used. This article examines how the antibody, radioisotope, chelator, and linker affect the safety and efficacy of RIT. The different approaches to dosing are also considered.

AB - Conventional chemotherapy regimens cure fewer than 50% of patients with aggressive non-Hodgkin's lymphoma, and fewer than 5% of patients with indolent lymphomas. However, the majority of patients remain responsive to remarkably low doses of external beam radiotherapy. A logical strategy for the treatment of non-Hodgkin's lymphoma is radioimmunotherapy (RIT); systemic radiation targeted to tumor cells using monoclonal antibodies. RIT involves continuous exposure to low-dose-rate radiation, with the intensity of the dose decreasing over time, and as such is distinct from conventional radiotherapy and chemotherapy. RIT has several advantages over monoclonal antibody therapy. For example, a functional immune system is not an absolute requirement to kill tumor cells, and, depending on the radiolabel used, β-emissions are effective over 100 to 500 cell diameters, resulting in a crossfire effect on nearby tumor cells. The crossfire effect enables the eradication of cells that are not necessarily targeted by the antibody, but are affected by the radiation. The success of RIT depends on which antibody and radioisotope is used. This article examines how the antibody, radioisotope, chelator, and linker affect the safety and efficacy of RIT. The different approaches to dosing are also considered.

UR - http://www.scopus.com/inward/record.url?scp=15744384597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744384597&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2005.01.011

DO - 10.1053/j.seminoncol.2005.01.011

M3 - Article

VL - 32

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 1

ER -